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Protein Therapeutics
for Cardiovascular Disease
It Is All About Delivery*
Tomoko Ichiki, MD, PHD, John C. Burnett, JR, MD
Rochester, Minnesota
During the last 2 decades, there have been seminal advances
in innovative therapeutics for human disease, which have
markedly reduced the burden of diseases in all clinical areas,
resulting in improved longevity and quality of life. This
impressive progress has been built on the creation of small
molecules taking advantage of a new level of expertise in
biological and medicinal chemistry. However, during the
last few years, we have witnessed a return to the use of
proteins and small peptides as innovative therapeutics, in
part, due to breakthroughs made by genomic medicine and
importantly by advances in protein delivery platforms. This
revival of interest in proteins and peptides has also been
driven by the decreasing approval of new small molecule
drugs.
See page 2550
What is clear is that proteins and peptides as therapeutics
hold great promise. Proteins and peptides go beyond small
molecules in terms of both specificity and safety as ligands of
human receptors and activators of specific molecular path-
ways, which as targets may achieve therapeutic goals (1). In
cardiovascular diseases, protein therapeutics is now an
exploding field. Today we are witnessing the emergence of
a diverse field of clinical and pre-clinical investigations using
proteins and peptides for a wide spectrum of cardiovascular
disease syndromes. For chronic ischemic disease syndromes
such as coronary artery disease and peripheral artery disease,
the ability to locally infect the heart or peripheral limb with
genes, which produce the peptide vascular endothelial
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the peptide Cenderitide and ANX042, respectively.growth factor, has been under investigation for over a
decade. Indeed, recent breakthroughs have been reported to
enhance and simplify delivering with integrating the vascu-
lar endothelial growth factor gene with a responsive hypoxic
element with nanoparticles to facilitate gene uptake and
regulation (2). The gene therapy approach represents a
strategy for cardiovascular protein therapeutics to enhance
the endogenous production of specific proteins.
In contrast to gene therapy, actual protein therapy and
delivery use well-defined and precisely structured proteins or
peptides, with previously defined therapeutic doses of an
individual protein or peptide for a specific disease state, and
with well-characterized biological actions. The use of pep-
tides is expanding in the broad area of heart failure and
beyond using natriuretic peptides and particulate guanylyl
cyclase receptor agonists as chronic therapeutics. As these
guanylyl cyclase receptors possess antihypertrophic, antifi-
brotic, proangiogenic, endothelial regenerating, aldosterone
suppressing, and renal preserving or enhancing properties,
these novel guanylyl cyclase activating peptides are in trials
for the inhibition of post–acute myocardial infarction
(AMI) remodeling, as well as delaying ventricular remod-
eling in mild systolic heart failure. The latter is delivered by
chronic subcutaneous administration (3,4).
In this issue of the Journal, Kawata et al. (5), advance the
eld of protein therapeutics for AMI in elegant pre-clinical
esearch. Their strategy is to go beyond an interventional
pproach and take advantage of thrombolytics and a novel
elivery system to achieve rapid coronary recanalization. It is
mportant to note that the area of thrombolysis represents
erhaps cardiology’s longest use of protein therapeutics. The
hanging practice of cardiology and the pivotal improve-
ent in AMI treatment began with the discovery of the
rotein streptokinase by William Smith Tillett in 1933, and
he continuing landmark clinical development by his stu-
ent Sol Sherry, which laid the foundation for its use as a
hrombolytic agent in the treatment of AMI (6,7).
Currently, reperfusion therapy for AMI is recommended
ithin 12 h from the onset of AMI to re-establish myocar-
ial blood flow from the culprit lesion to reduce myocardial
ecrosis and remodeling, which would improve mortality
nd morbidity in AMI patients. From several clinical trials,
ercutaneous coronary intervention (PCI) demonstrated
avorable results as compared with thrombolytic therapy;
owever, a certain number of patients still required throm-
olysis in individual settings, such as patient characteristics,
ime from onset, or accessing a hospital where there are
mergency PCI capabilities in place (8). The main issues of
hrombolytic therapy that remain are a less successful (
eperfusion) rate and higher risk of serious hemorrhage than
CI.
In this seminal study by Kawata et al. (5), who elegantly
ocused on thrombolytic therapy to improve those issues,
he investigators report the development of a “stealth”
echnology in which a thrombolytic protein (tissue type
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large protein that recognizes von Willebrand factor, which
is expressed on the surface of platelets. This therapeutic
protein platform together with zinc ions suppresses tPA
activity in vitro and can be activated in vivo by ultrasound,
which therefore represents the “stealth” delivery platform
permitting the protein complex to circulate with little
activity and which then can be activated ultrasonically near
an active thrombus (9). This highly novel pre-clinical
approach advanced by the investigators was comprehensive
with testing of the concept of a gelatin, tPA, and zinc
complex in vitro and then taking this protein delivery system
to a mouse model of thrombosis to establish potential
feasibility. Most importantly, they then translated their
findings to a swine model of AMI.
The key findings were that these gelatin nanoparticles
with tPA bind to von Willebrand factor ex vivo, and in a
mouse model of thrombus these nanoparticles accumulate at
the site of thrombosis. In the swine model of AMI,
circulating levels of tPA were modest after injection of the
gelatin/tPA nanoparticles, thus protecting tissues remote
from coronary thrombosis from high active tPA concentra-
tions. Importantly, transthoracic ultrasound locally and
completely activated these tPA-carrying nanoparticles in the
model of AMI. Indeed, this innovative protein therapeutic
strategy recanalized 9 of 10 pigs in 30 min. These findings
may translate into an improved AMI therapeutic strategy
with thrombolysis because of the novel tPA nanoparticles,
which allow targeting only the fresh thrombosis and do so
with lower doses, which may decrease a risk of serious
bleeding complications.
These studies are of high clinical importance, and as
stated by the investigators, this innovative drug delivery
system “may provide novel reperfusion therapy in AMI
patients which can be theoretically started in an ambulance,
and is also applicable in the treatment of stroke, pulmonary
thromboembolism, peripheral arterial thrombosis and leg
vein thrombosis.” The investigators are to be congratulated
for their pioneering work and are anxious to expand the
study into other thrombotic diseases as well in the future.
It is worth making some additional comments that build
on the investigators’ statement, which implies the use of
early intervention with this novel reperfusion technology.
First, cardiology and the healthcare delivery system have
made substantial progress in door-to-balloon time for AMI.
Krumholz et al. (10), writing in 2011, reported an analysis
of all patients reported by hospitals to the Centers for
Medicare and Medicaid Services for inclusion in the time-
to-PCI inpatient measure from 2005 to 2010. Their report
clearly documented impressive progress in the United States
in reducing door-to-balloon time. To complement this
recent report is the important study by Shiomi et al. (11)
from Japan. These investigators reported key findings from
the CREDO-Kyoto (Coronary Revascularization Demon-
strating Outcome Study in Kyoto) study on onset-to-
balloon versus door-to-balloon times and outcomes. Impor-tantly, short onset-to-balloon time was associated with
better 3-year outcomes in ST-segment elevation AMI
patients having PCI, whereas the benefit of short door-to-
balloon time was limited to patients who presented early.
These studies shift our attention to this critical period prior
to hospital arrival. Perhaps the “next frontier” of technolo-
gies advanced by Kawata et al. (5) offers a view to the future
in which a specialized mobile emergency chest pain unit
could emerge that travels to the patient. Such a mobile unit
with electrocardiogram telemedicine and a point of care
troponin measurement together with clinical judgment es-
tablish the ST-segment elevation AMI diagnosis. An intra-
venous injection of tPA nanoparticles follows and they are
activated by transthoracic ultrasound at the site of coronary
thrombosis to initiate immediate reperfusion to be finalized
as required in the catheterization laboratory. Clearly, these
thoughts represent an idealized healthcare delivery system,
but such visions of future AMI therapy are becoming clearer
and more feasible.
What are the next steps based on the current study?
We believe that continued work in the swine model of
AMI might help refine timing and long-term outcomes.
Indeed one could also combine the swine AMI model
with a swine atherosclerosis model to better mimic
human coronary artery disease. Would there be benefit
too of chronic therapy following recanalization in the
pig? These are all important questions, but it is hoped
that the investigators will now begin to lay the founda-
tion for proof-of-concept testing in human studies.
Indeed, the technology is exciting and its potential in
human AMI is high for success, which now will require
clinical trials to confirm safety and efficacy.
In summary, the field of cardiovascular protein therapeu-
tics is undergoing an exciting rejuvenation due to advances
in protein biochemistry and novel delivery systems. No
doubt, we are at only the beginning of a new era in this
therapeutic arena, which should enhance our efforts to
reduce the burden of cardiovascular disease.
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